Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019031923) PHARMACEUTICAL COMPOSITION COMPRISING MIR-150 INHIBITOR AS EFFECTIVE INGREDIENT FOR IMMUNOPOTENTIATION AND METHOD FOR SCREENING IMMUNOPOTENTIATOR
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/031923 International Application No.: PCT/KR2018/009190
Publication Date: 14.02.2019 International Filing Date: 10.08.2018
IPC:
A61K 48/00 (2006.01) ,C12Q 1/6883 (2018.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
[IPC code unknown for C12Q 1/6883]
Applicants:
한국생명공학연구원 KOREA RESEARCH INSTITUTE OF BIOSCEINCE AND BIOTECHNOLOGY [KR/KR]; 대전시 유성구 과학로 125 125 Gwahak-ro Yuseong-gu Daejeon 34141, KR
연세대학교 산학협력단 INDUSTRY-ACADEMIC COOPERATION, YONSEI UNIVERSITY [KR/KR]; 서울특별시 서대문구 연세로 50 Yonsei-ro, 50 Seodaemun-gu Seoul 03722, KR
Inventors:
김태돈 KIM, Tae-Don; KR
하상준 HA, Sang Jun; KR
최인표 CHOI, In Pyo; KR
반영호 BAN, Young Ho; KR
서상환 SEO, Sang-Hwan; KR
정초록 JUNG, Cho Rok; KR
Agent:
제일특허법인 FIRSTLAW P.C.; 서울특별시 서초구 마방로 60 60 Mabang-ro, Seocho— gu Seoul 06775, KR
Priority Data:
10-2017-010194310.08.2017KR
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING MIR-150 INHIBITOR AS EFFECTIVE INGREDIENT FOR IMMUNOPOTENTIATION AND METHOD FOR SCREENING IMMUNOPOTENTIATOR
(FR) COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE MIR-150 À TITRE DE PRINCIPE ACTIF POUR L'IMMUNOPOTENTIALISATION ET PROCÉDÉ D'IDENTIFICATION PAR CRIBLAGE D'UN IMMUNOPOTENTIALISATEUR
(KO) miR-150 저해제를 유효성분으로 포함하는 면역 활성 증진용 약학적 조성물 및 면역 증진제 스크리닝 방법
Abstract:
(EN) The present invention relates to a pharmaceutical composition comprising a miR-150 inhibitor as an effective ingredient for immunopotentiation and a method for screening an immunopotentiator. In addition, the present invention provides a method for screening an immunopotentiator capable of enhancing an immune response by regulating an expression level of miR-150. Through embodiments, the present invention revealed the enhancement of miR-150-deficient mice in inducing differentiation into memory CD8+ T cells. It was also revealed that memory CD8+ T cell differentiation was induced in miR-150-deficient mice, regardless of kinds of the pathogens. Therefore, a composition comprising a miR-150 inhibitor as an effective ingredient can be used as an immunopotentiator, finding effective applications in the prevention or treatment of cancer or infectious diseases.
(FR) La présente invention concerne une composition pharmaceutique comprenant un inhibiteur de miR-150 à titre de principe actif pour l'immunopotentialisation et un procédé d'identification par criblage d'un immunopotentialisateur. Un procédé d'identification par criblage d'un immunopotentialisateur capable d'améliorer une réponse immunitaire par régulation d'un niveau d'expression de miR-150 est en outre décrit. Des modes de réalisation selon la présente invention ont révélé une amélioration chez la souris déficiente en miR-150 de l'induction d'une différenciation en cellules T CD8+ "mémoire". Il a également été révélé que la différenciation en cellules T CD8+ "mémoire" a été induite chez la souris déficiente en miR-150, indépendamment des types de pathogènes. Par conséquent, une composition comprenant un inhibiteur de miR-150 à titre de principe actif peut être utilisée comme immunopotentialisateur, pour trouver des applications efficaces dans la prévention ou le traitement du cancer ou de maladies infectieuses.
(KO) 본 발명은 miR-150 저해제를 유효성분으로 포함하는 면역 활성 증진용 약학적 조성물 및 면역 증진제 스크리닝 방법에 관한 것이다. 또한, miR-150의 발현량을 조절함으로써, 면역 반응을 증진시킬 수 있는 면역 증진제를 스크리닝 하는 방법을 제공한다. 본 발명은 일 실시예들을 통해, miR-150가 결핍된 마우스에서 기억 CD8+ T 세포의 분화 유도가 향상됨을 보였다. 또한, miR-150가 결핍된 마우스에서 기억 CD8+ T 세포 분화는 병원체의 종류에 관계없이 유도됨을 확인하였다. 따라서, miR-150를 저해시키는 물질을 유효성분으로 포함하는 조성물은 면역 증진제로 활용하여 암 또는 감염성 질환의 예방 또는 치료에 효과적으로 사용될 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)